Articles from Arima Genomics, Inc.

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced new data to be presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, FL from December 6–9, 2025.

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced it will be presenting new data this week at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Exposition taking place in Boston, Massachusetts from November 11-15, 2025. Scientists from Arima and Labcorp will present research conducted in collaboration demonstrating that Hi-C sequencing technology—commercially available for clinical use in lymphoma as the Aventa™ Lymphoma test—clarifies diagnoses.

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced that the Aventa™ Lymphoma test has received “Clinical Diagnostics Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that recognizes standout life sciences and biotechnology companies, and products around the globe.

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing that the Aventa Lymphoma test turns ambiguous FISH (fluorescent in situ hybridization) results into clear clinical answers for patients with diffuse large B-cell lymphoma (DLBCL).

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the broad commercial launch of the Aventa Lymphoma test at the Society of Hematologic Oncology (SOHO 2025) meeting in Houston, Texas.

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the appointment of Tom Willis, PhD, as chief executive officer and the close of a $22 million Series C financing led by Illumina Ventures. The round includes participation from genomics pioneers John Stuelpnagel and Mostafa Ronaghi, PhD, as well as existing backers Co-Win Ventures and Berkeley Catalyst Fund. The leadership transition and new capital mark a strategic pivot as Arima strengthens its focus on transforming oncology testing.

Arima Genomics, Inc. (Arima), a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today announced the publication of a study in The Journal of Molecular Diagnostics showing its proprietary technology detected clinical structural variants missed by conventional clinical tests. Conducted in collaboration with researchers from NYU Langone Health, Weill Cornell School of Medicine, Scripps Cancer Center, Moores Cancer Center at the University of California, San Diego, and the University of Colorado School of Medicine, the retrospective study found that Arima’s technology identified gene fusions or rearrangements in 71% of cases where standard molecular techniques failed. Importantly, in 14% of these cases where no driver had been found by other techniques, a clinically actionable variant was identified.

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today announced the appointment of three seasoned executives to bolster its advanced diagnostics and clinical affairs capabilities. David Duvall joins as Senior Vice President, Commercial; Alex Hastie, Ph.D., as Vice President, Medical Affairs; and William (Bill) Ricketts, Ph.D., as Associate Vice President, Clinical Evidence Generation. Their combined expertise underscores Arima Genomics’ commitment to driving 3D genomic solutions in both research and clinical settings.

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today announced the appointment of Gabrielle ‘Gabi’ Raia to the newly created position of Senior Vice President of Discovery and Clinical Sales. In this role, Gabi will be responsible for managing the existing business with research customers as well as facilitating the adoption of 3D genomics into the translational and clinical communities, including healthcare providers.

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians seeking to improve human health, today announced the appointment of diagnostics industry veterans John Palma, PhD, and Don Hardison to its Board of Directors. In addition to Dr. Palma and Mr. Hardison, the Arima Genomics Board of Directors consists of Elizabeth Brady, Siddarth Selvaraj, and Xin Huang.

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to empower researchers and clinicians seeking to improve human health, and Pierian, now a part of Velsera, the precision engine company which enables the democratization of omic data across clinical and research applications, today announced co-marketing and licensing agreements that will provide enhanced gene fusion detecting capabilities to clinical labs. Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting. The combined solution will enable clinical laboratories to more easily implement sample-to-answer Arima gene fusion testing, helping them identify gene fusions and other structural variants.

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to empower researchers and clinicians seeking to improve human health, today announced an agreement to make an Arima next-generation sequencing (NGS)-based test available to clinicians for patient management through Protean BioDiagnostic’s CLIA-certified, CAP-accredited laboratory in Orlando, Florida. The new testing service, using Arima’s novel genomic technology, will identify clinically actionable gene fusions in tumor tissue from patients with cancer, and is anticipated to be available for order in the first half of 2023.

Arima Genomics, Inc., the leader in 3D genomics, today announced that it is launching into the world of single-cell analyses by enabling a team of researchers to map the 3D genome of the human brain, cell by cell. The work is being carried out at multiple institutions including the Salk Institute, and the University of California, Los Angeles, under the umbrella of The BRAIN Initiative Cell Atlas Network (BICAN) and the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

Arima Genomics, Inc., the leader in 3D genomics, today announced a new partnership with Basepair to empower scientists with new options for bioinformatic analysis of 3D genomic data. The deal will make the Arima Genomics bioinformatics pipelines more accessible to bench scientists by making it available through a user-friendly interface, decreasing compute time, improving data handling and sharing, and generating easy-to-understand reports.

Arima Genomics, Inc., the leader in 3D genomics, today announced that new data on the detection of actionable structural variants from cancer samples embedded in formalin-fixed, paraffin-embedded (FFPE) tissues will be presented at the Association of Molecular Pathology Annual Meeting and Expo in Phoenix, Ariz. The data, developed in partnership with researchers from NYU Langone Health, shows how Arima Genomics’ 3D genomics tools were useful in detecting previously undetected gene rearrangements, fusions, and other structural variants of clinical significance, meaning that those variants were diagnostic, prognostic, the target of on-market therapies, or therapies being investigated in ongoing clinical trials.

Arima Genomics, Inc., the leader in 3D genomics, today announced the close of its $7 million Series B Preferred Stock financing round. New investors Genetron Health (NASDAQ: GTH), Tech Coast Angels, Ladder Ventures, and Hiaqua Investments were joined by existing investors Agilent Technologies (NYSE: A), Co-win Ventures, Vectr Ventures, and Berkeley Catalyst Fund in partnering with the company to support its long-term growth and commercial expansion.

Arima Genomics, Inc., the leader in 3D genomics, today announced the launch of new solutions for structural variant detection and gene regulation analysis. These solutions enhance the company’s market-leading portfolio of 3D genomics tools that help researchers unlock new insights for disease research.